Hostname: page-component-76fb5796d-r6qrq Total loading time: 0 Render date: 2024-04-29T04:57:51.770Z Has data issue: false hasContentIssue false
  • English
  • Français

Deprenyl in Parkinson’s Disease: Mechanisms, Neuroprotective Effect, Indications and Adverse Effects

Published online by Cambridge University Press:  18 September 2015

Paul Vezina ,
Erich Mohr  and
David Grimes
Paul Vezina*
Affiliation:
Neurosciences Unit, Loeb Medical Research Institute and Division of Neurology, Ottawa Civic Hospital and the Institute of Mental Health Research, Royal Ottawa Hospital, University of Ottawa, Ottawa
Erich Mohr
Affiliation:
Neurosciences Unit, Loeb Medical Research Institute and Division of Neurology, Ottawa Civic Hospital and the Institute of Mental Health Research, Royal Ottawa Hospital, University of Ottawa, Ottawa
David Grimes
Affiliation:
Neurosciences Unit, Loeb Medical Research Institute and Division of Neurology, Ottawa Civic Hospital and the Institute of Mental Health Research, Royal Ottawa Hospital, University of Ottawa, Ottawa
*
Division of Neurology and Loeb Medical Research Institute, Ottawa Civic Hospital, 1053 Carling Ave., Ottawa, Ontario, Canada K1Y 4E9
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Deprenyl is a synthetic, selective inhibitor of the monoamine oxidase-B enzyme system. The mechanism of its beneficial effect in early and advanced Parkinson’s disease is not settled. Increased striatal dopamine accumulation, sensitization of surviving dopamine neurons with increased dopamine production and reduced nigro-striatal toxicity may all contribute. The standard daily dose of deprenyl is 10 mg. Selectivity may be lost at higher doses. Deprenyl is especially indicated in untreated patients, improving up to 50 percent of patients with mild motor fluctuations. Major symptomatic benefit also occurs in occasional levodopa treated patients. Adverse effects are common, however. Increase dyskinesias, confusion and hallucinations, nausea and postural hypotension may necessitate drug withdrawal or the use of low dose regimens. Caution should be exercised with older patients, those with ulcer disease, which may be worsened by deprenyl, and individuals with active ischemic heart disease where the safety of this drug is not yet clear.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 19 , Issue S1: 3rd Canadian Conference on Neurodegenerative Diseases , February 1992 , pp. 142 - 146
Copyright
Copyright © Canadian Neurological Sciences Federation 1992

References

1.Elizan, TS, Yahr, MD, Moros, DA, et al. Selegiline as an adjunct to conventional levodopa therapy in Parkinson’s disease. Arch Neurol 1989; 46: 1280–1283.CrossRefGoogle ScholarPubMed
2. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1989; 321: 1364–1371.CrossRefGoogle Scholar
3.Shoulson, I.Protective therapy for Parkinson’s disease. In: Roller, WC, Paulson, G, eds. Therapy of Parkinson’s disease. New York: Dekker, 1990; 357–368.Google Scholar
4.Lees, AJ, Shaw, KM, Kohout, U, et al. Deprenyl in Parkinson’s disease. Lancet 1977; 2: 791–795.CrossRefGoogle ScholarPubMed
5.Birkmayer, W, Knoll, J, Riederer, PJ.Increased life expectancy resulting from addition of deprenyl to Madopar treatment in Parkinson’s disease. Neural Transm 1985; 65: 113–127.CrossRefGoogle Scholar
6.Cohen, G, Spina, MB.Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol 1989; 26: 689–690.CrossRefGoogle ScholarPubMed
7.Furtado, JCS, Mazurek, MF.MPTP-induced neurotoxicity and the quest for a preventative therapy for Parkinson’s disease. Can J Neurol Sci 1991; 18: 77.CrossRefGoogle ScholarPubMed
8.Reynolds, GP, Elsworth, JD, Blau, K, et al. Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol 1978; 6: 542.CrossRefGoogle ScholarPubMed
9.Paterson, IA, Juorio, AV, Boulton, AA.Possible mechanisms of action of deprenyl in parkinsonism. Lancet 1990; 336: 183.CrossRefGoogle ScholarPubMed
10.Schachter, M, Price, PA, Parkes, JD.Deprenyl in narcolepsy. Lancet 1979; 1: 831–832.CrossRefGoogle ScholarPubMed
11.Mantegazza, P, Riva, MJ.Amphetamine-like activity of B-phenethy-lamine after a monoamine oxidase inhibitor in vivo. Pharm Pharmacol 1963; 15: 472–478.CrossRefGoogle Scholar
12.Knoll, J.The possible mechanism of action of (-)deprenyl in Parkinson’s disease. J Neural Transm 1978; 43: 117.CrossRefGoogle ScholarPubMed
13.Zsilla, G, Foldi, P, Held, G, et al. The effect of repeated doses of (-)deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline. Pol J Pharmacol Pharm 1986; 86: 211–217.Google Scholar
14.Kerecsen, L, Kalasz, H, Tarcail, J, et al. Measurement of DA and DOPAC release from rat striatal preparations in vitro using HPLC with electrochemical detection. In: Kalasz, and Ettre, , eds. Chromotography: the State of the Art. Budapest: Akademiai Kiado, 1985.Google Scholar
15.Mann, JJ, Gershon, S.Deprenyl, a selective monoamine oxidase type B inhibitor in endogenous depression. Life Sci 1980; 26: 877–882.CrossRefGoogle ScholarPubMed
16.Knoll, J.Role of B-type monoamine oxidase inhibition in the treatment of Parkinson’s disease. In: Shah, and Donald, , eds. Movement disorders. New York: Plenum, 1986.Google Scholar
17.Glover, V, Sandler, M, Owen, F, et al. Dopamine is a monoamine oxidase B substrate in man. Nature 1977; 265: 80–81.CrossRefGoogle ScholarPubMed
18.Westlund, KN, Denney, RM, Kochersperger, LM, et al. Distinct monoamine oxidase A and B populations in primate brain. Science 1985; 230: 181–183.CrossRefGoogle Scholar
19.Glover, V, Willoughby, J, Sandler, M.Histochemical localization of MAO A and B in brain. Pharmacol Toxicol 1987; 60: S22.Google Scholar
20.Levitt, P, Pintar, JE, Breakefield, XO.Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci 1982; 79: 6385–6389.CrossRefGoogle ScholarPubMed
21.Robinson, TE, Becker, JB.Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev 1986; 11: 157–198.CrossRefGoogle Scholar
22.Marsden, CD.Parkinson’s disease. Lancet 1990; 335 (1): 948–952.CrossRefGoogle ScholarPubMed
23.Grimes, JD, Hassan, MN, Thakar, J.Antioxidant therapy in Parkinson’s disease. Can J Neurol Sci 1987; 14: 483–487.CrossRefGoogle ScholarPubMed
24.Tetrud, JW, Langston, JW.The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 1989; 245: 519–522.CrossRefGoogle ScholarPubMed
25.Kofman, OS.Deprenyl: protective vs symptomatic effect. Can J Neurol Sci 1991; 18: 83–85.CrossRefGoogle ScholarPubMed
26.Grimes, JD.Deprenyl: the exciting possibility of protective effect. Can J Neurol Sci 1991; 18: 85–86.CrossRefGoogle ScholarPubMed
27.Teravainen, H.Selegiline in Parkinson’s disease. Acta Neurol Scand 1990; 81: 333–336.CrossRefGoogle ScholarPubMed
28.Diamond, SG, Markham, CH, Treciokas, LJ, et al. Double-blind trial of pergolide in Parkinson’s disease. Neurology 1985; 35: 291–295.CrossRefGoogle Scholar
29.Knoll, J.Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand 1983; 95: 57–80.CrossRefGoogle ScholarPubMed
30. Parkinson Study Group. Datatop: a multicentre controlled clinical trial in early Parkinson’s disease. Arch Neurol 1989; 46: 1052–1060.CrossRefGoogle Scholar
31.Lees, AJ, Frankel, J, Eatough, FV, et al. Acta Neurol Scand 1989; 126: 139–145.CrossRefGoogle Scholar
32.Birkmayer, W, Riederer, P, Ambrozi, L, et al. Implications of combined treatment with Madopar and L-deprenyl in Parkinson’s disease. Lancet 1977; 2: 439–443.CrossRefGoogle Scholar
33.Golbe, LI.Long-term efficacy and safety of deprenyl (selegeline) in advanced Parkinson’s disease. Neurology 1989; 39: 1109–1111.CrossRefGoogle Scholar
34.Rinne, UK, Siirtola, T, Sonninen, VL.L-deprenyl treatment of on-off phenomenon in Parkinson’s disease. J Neural Transm 1978; 43: 253–262.CrossRefGoogle Scholar
35.Mann, JJ, Fox-Aarons, S, Wilner, PJ, et al. A controlled study of the antidepressant efficacy and side effects of (-)deprenyl. Arch Gen Psychiatry 1989; 46: 45–50.CrossRefGoogle ScholarPubMed
36.Adolfsson, R, Gottfries, CG, Wiberg, A, et al. Increased activity of brain and platelet monoamine oxidase in dementia of the Alzheimer’s type. Life Sci 1989; 27: 1029–1034.CrossRefGoogle Scholar
37.Harman, D.Role of free radicals in aging and disease. In: Johnson, HA, ed. Relations between normal signs and disease. New York: Raven Press, 1985; 45–84.Google Scholar
38.Sandler, M.Monoamine oxidase inhibitors and their pharmacological significance. Acta Neurol Scand 1983; 95: 37–41.CrossRefGoogle ScholarPubMed
39.Goldstein, M, Lew, JY.Deprenyl for the treatment of early Parkinson’s disease. N Engl J Med 1990; 21: 1526–1527.Google Scholar
40.Birkmayer, W.Deprenyl (selegiline) in the treatment of Parkinson’s disease. Acta Neurol Scand 1983; 95: 103–106.CrossRefGoogle ScholarPubMed
41.Knoll, J.The pharmacology of selegiline ((-)deprenyl). New aspects. Acta Neurol Scand 1989; 126: 83–91.CrossRefGoogle ScholarPubMed
42.Newman, RP, LeWitt, PA, Jaffe, M, et al. Motor function in the normal aging population: treatment with levodopa. Neurology 1985; 35: 571–573.CrossRefGoogle ScholarPubMed
43.Heinonen, EH, Rinne, UK.Selegiline in the treatment of Parkinson’s disease. Acta Neurol Scand 1989; 126: 103–111.Google ScholarPubMed
44.Golbe, LI, Lieberman, AN, Muenter, MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson’s disease. Clin Neuropharmacol 1988; 11: 45–55.CrossRefGoogle ScholarPubMed
45.Furst, SR, Fallon, SP, Reznik, GN, et al. Myocardial infarction after inhalation of methamphetamine. N Engl J Med 1990; 323: 1147–1148.Google ScholarPubMed
46.Carson, P, Oldroyd, K, Phadke, K.Myocardial infarction due to amphetamine. Br Med J 1987; 294; 1525–1526.CrossRefGoogle ScholarPubMed
47.Heinonen, EH, Myllyla, V, Sotaniemi, K, et al. Pharmacokinetics and metabolism of selegiline. Acta Neurol Scand 1989; 126: 93–99.Google ScholarPubMed
48.Saint-Hilaire, M, Feldman, RG, Durso, R.Deprenyl for the treatment of early Parkinson’s disease. N Engl J Med 1990; 322: 1527.Google Scholar
49.Stern, GM, Lees, AJ, Hardie, RJ, et al. Clinical pharmacological problems of deprenyl (selegiline) treatment in Parkinson’s disease. Acta Neurol Scand 1983; 95: 113–116.CrossRefGoogle ScholarPubMed
50.Suchowersky, O, de Vries, J.Possible interactions between deprenyl and prozac. Can J Neurol Sci 1990; 17: 352–353.CrossRefGoogle ScholarPubMed
51.Bouchard, RH, Pourcher, E, Vincent, P.Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1989; 146: 1352–1353.Google Scholar